A focused review of visible light therapies for vitiligo

Abstract Background Vitiligo can be challenging to treat and exhibit an unpredictable clinical course. Phototherapy in the form of visible light can achieve both repigmentation and depigmentation outcomes in vitiligo, with minimal associated adverse events. This review focuses on the mechanistic understandings and clinical outcomes of visible light‐based treatments for vitiligo. Methods Articles were retrieved from PubMed starting from May 1965 until August 2023, yielding 496 unique articles. We conducted title, abstract, and full‐text screening to identify articles describing the use of visible light (380–750 nm), either as part of combination therapy or as monotherapy, for repigmentation or depigmentation treatment in vitiligo. Results Twenty‐seven articles met inclusion criteria, offering preclinical and clinical data regarding the utilization of helium‐neon laser (red light) and blue light‐emitting diodes (LEDs) as methods of repigmentation therapy in vitiligo. Preclinical and clinical data on the utilization of Q‐switched ruby laser (694 nm) and frequency‐doubled (FD) Nd:YAG laser (532 nm) for vitiligo depigmentation therapy were also identified. Conclusion While limited by small studies and a lack of standardized administration of phototherapy, the evidence for visible light's effectiveness in managing vitiligo is encouraging. Red light therapy using He–Ne lasers and blue light therapy via LEDs can stimulate repigmentation in patients with vitiligo with minimal adverse events. Q‐switched ruby and FD Nd:YAG lasers provide viable, visible light depigmentation options, either alone or with topical agents. With limited clinical data, larger studies are needed to validate the efficacy of visible light therapy in treating vitiligo and to better understand its long‐term outcomes.